Cardiff Oncology Stock Performance
| CRDF Stock | USD 1.60 0.02 1.27% |
The firm shows a Beta (market volatility) of 2.57, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cardiff Oncology will likely underperform. At this point, Cardiff Oncology has a negative expected return of -0.17%. Please make sure to confirm Cardiff Oncology's kurtosis, and the relationship between the value at risk and rate of daily change , to decide if Cardiff Oncology performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Cardiff Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's fundamental indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders. ...more
Last Split Factor 1:6 | Dividend Date 2019-02-20 | Last Split Date 2019-02-20 |
1 | Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference | 11/24/2025 |
2 | How Cardiff Oncology Inc. stock stacks up against competitors - July 2025 Selloffs Reliable Trade Execution Plans - Newser | 12/04/2025 |
3 | Cardiff Oncology to Present at Sidotis Year-End Virtual Investor Conference | 12/08/2025 |
4 | Cardiff Oncology, Inc. Given Average Rating of Hold by Brokerages - MarketBeat | 12/17/2025 |
5 | Stock Traders Purchase High Volume of Cardiff Oncology Call Options | 12/23/2025 |
6 | Analysts Offer Predictions for CRDF FY2025 Earnings - MarketBeat | 01/06/2026 |
7 | Cardiff Oncology What Storms Can We Expect In 2026 The Case For Measured Enthusiasm - Seeking Alpha | 01/13/2026 |
8 | Insider Trading | 01/27/2026 |
9 | Cardiff Oncology Valuation Check After New Onvansertib Phase 2 Data And Leadership Changes | 01/29/2026 |
| Begin Period Cash Flow | 21.7 M | |
| Total Cashflows From Investing Activities | 13.7 M |
Cardiff Oncology Relative Risk vs. Return Landscape
If you would invest 206.00 in Cardiff Oncology on November 17, 2025 and sell it today you would lose (46.00) from holding Cardiff Oncology or give up 22.33% of portfolio value over 90 days. Cardiff Oncology is currently does not generate positive expected returns and assumes 6.5486% risk (volatility on return distribution) over the 90 days horizon. In different words, 58% of stocks are less volatile than Cardiff, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cardiff Oncology Target Price Odds to finish over Current Price
The tendency of Cardiff Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.60 | 90 days | 1.60 | about 92.93 |
Based on a normal probability distribution, the odds of Cardiff Oncology to move above the current price in 90 days from now is about 92.93 (This Cardiff Oncology probability density function shows the probability of Cardiff Stock to fall within a particular range of prices over 90 days) .
Cardiff Oncology Price Density |
| Price |
Predictive Modules for Cardiff Oncology
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cardiff Oncology. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cardiff Oncology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cardiff Oncology Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Cardiff Oncology is not an exception. The market had few large corrections towards the Cardiff Oncology's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cardiff Oncology, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cardiff Oncology within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.44 | |
β | Beta against Dow Jones | 2.57 | |
σ | Overall volatility | 0.51 | |
Ir | Information ratio | -0.05 |
Cardiff Oncology Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cardiff Oncology for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cardiff Oncology can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Cardiff Oncology generated a negative expected return over the last 90 days | |
| Cardiff Oncology has high historical volatility and very poor performance | |
| Cardiff Oncology may become a speculative penny stock | |
| The company reported the previous year's revenue of 683 K. Net Loss for the year was (45.43 M) with loss before overhead, payroll, taxes, and interest of (39.47 M). | |
| Cardiff Oncology currently holds about 122.01 M in cash with (37.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.82, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cardiff Oncology has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Insider Trading |
Cardiff Oncology Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cardiff Stock often depends not only on the future outlook of the current and potential Cardiff Oncology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cardiff Oncology's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 47.6 M | |
| Cash And Short Term Investments | 91.7 M |
Cardiff Oncology Fundamentals Growth
Cardiff Stock prices reflect investors' perceptions of the future prospects and financial health of Cardiff Oncology, and Cardiff Oncology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cardiff Stock performance.
| Return On Equity | -1.03 | ||||
| Return On Asset | -0.53 | ||||
| Operating Margin | (99.78) % | ||||
| Current Valuation | 46.85 M | ||||
| Shares Outstanding | 67.36 M | ||||
| Price To Earning | (0.48) X | ||||
| Price To Book | 2.18 X | ||||
| Price To Sales | 215.12 X | ||||
| Revenue | 683 K | ||||
| Gross Profit | (39.47 M) | ||||
| EBITDA | (48.25 M) | ||||
| Net Income | (45.43 M) | ||||
| Cash And Equivalents | 122.01 M | ||||
| Cash Per Share | 2.82 X | ||||
| Total Debt | 1.52 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 15.02 X | ||||
| Book Value Per Share | 0.73 X | ||||
| Cash Flow From Operations | (37.69 M) | ||||
| Earnings Per Share | (0.79) X | ||||
| Market Capitalization | 107.78 M | ||||
| Total Asset | 97.19 M | ||||
| Retained Earnings | (384.18 M) | ||||
| Working Capital | 81.63 M | ||||
| Current Asset | 16.9 M | ||||
| Current Liabilities | 4.78 M | ||||
About Cardiff Oncology Performance
By analyzing Cardiff Oncology's fundamental ratios, stakeholders can gain valuable insights into Cardiff Oncology's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cardiff Oncology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cardiff Oncology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -11.9 K | -11.3 K | |
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.67) | (0.63) | |
| Return On Assets | (0.42) | (0.44) | |
| Return On Equity | (0.63) | (0.66) |
Things to note about Cardiff Oncology performance evaluation
Checking the ongoing alerts about Cardiff Oncology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cardiff Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cardiff Oncology generated a negative expected return over the last 90 days | |
| Cardiff Oncology has high historical volatility and very poor performance | |
| Cardiff Oncology may become a speculative penny stock | |
| The company reported the previous year's revenue of 683 K. Net Loss for the year was (45.43 M) with loss before overhead, payroll, taxes, and interest of (39.47 M). | |
| Cardiff Oncology currently holds about 122.01 M in cash with (37.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.82, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cardiff Oncology has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Insider Trading |
- Analyzing Cardiff Oncology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cardiff Oncology's stock is overvalued or undervalued compared to its peers.
- Examining Cardiff Oncology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cardiff Oncology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cardiff Oncology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cardiff Oncology's stock. These opinions can provide insight into Cardiff Oncology's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cardiff Stock analysis
When running Cardiff Oncology's price analysis, check to measure Cardiff Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardiff Oncology is operating at the current time. Most of Cardiff Oncology's value examination focuses on studying past and present price action to predict the probability of Cardiff Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardiff Oncology's price. Additionally, you may evaluate how the addition of Cardiff Oncology to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |